Search

Your search keyword '"M. S. Berger"' showing total 24 results
Start Over Author "M. S. Berger" Topic business
24 results on '"M. S. Berger"'

1. Diagnosis of Sweet's syndrome in otolaryngology

Author

Marijke R van Dijk, Anouk W M A Schaeffers, Digna M A Kamalski, and Danique M S Berger

Subjects
Sweet's syndrome, Adult, medicine.medical_specialty, Referral, medicine.diagnostic_test, business.industry, Signs and symptoms, General Medicine, medicine.disease, Dermatology, Skin Diseases, Sweet Syndrome, Lesion, Leukemia, Myeloid, Acute, Otolaryngology, Otorhinolaryngology, Biopsy, medicine, Humans, In patient, Female, Myeloid leukaemia, medicine.symptom, business, Skin
Abstract

Sweet’s syndrome (acute febrile neutrophilic dermatosis) consists of acute onset of painful cutaneous erythematous lesions, mostly found in the upper extremities followed by the head and neck region, particularly in patients with underlying malignancies. We describe the case of a woman in her mid-30s, who was treated for acute myeloid leukaemia and presented with a severe painful and progressive erythematous lesion of the retroauricular skin. Clinical features, laboratory tests, blood cultures and histological biopsy yielded a diagnosis of Sweet’s syndrome. The treatment consisted of oral and topical corticosteroids and her signs and symptoms resolved within 1 week. Although Sweet’s syndrome is uncommon, awareness among otolaryngologists is crucial to ensure a prompt diagnosis, cure and referral to an oncologist (if not already involved) for patients with Sweet’s syndrome in the head and neck area.

Published
2023

2. OMICS AND PROGNSTIC MARKERS

Author

K. Adachi, H. Sasaki, S. Nagahisa, K. Yoshida, N. Hattori, Y. Nishiyama, T. Kawase, M. Hasegawa, M. Abe, Y. Hirose, A. Alentorn, Y. Marie, S. Poggioli, H. Alshehhi, B. Boisselier, C. Carpentier, K. Mokhtari, L. Capelle, D. Figarella-Branger, K. Hoang-Xuan, M. Sanson, J.-Y. Delattre, A. Idbaih, S. Yust-Katz, M. Anderson, A. Olar, A. Eterovic, N. Ezzeddine, K. Chen, H. Zhao, G. Fuller, K. Aldape, J. de Groot, N. Andor, J. Harness, S. G. Lopez, T. L. Fung, H. W. Mewes, C. Petritsch, A. Arivazhagan, K. Somasundaram, K. Thennarasu, P. Pandey, B. Anandh, V. Santosh, B. Chandramouli, A. Hegde, P. Kondaiah, M. Rao, R. Bell, R. Kang, C. Hong, J. Song, J. Costello, R. Nagarajan, B. Zhang, A. Diaz, T. Wang, L. Bie, Y. Li, H. Liu, W. F. C. Luyo, M. H. Carnero, M. E. P. Iruegas, A. R. Morell, M. C. Figueiras, R. L. Lopez, C. F. Valverde, A. K.-Y. Chan, J. C.-S. Pang, N. Y.-F. Chung, K. K.-W. Li, W. S. Poon, D. T.-M. Chan, Y. Wang, H.-a. K. Ng, M. Chaumeil, P. Larson, H. Yoshihara, D. Vigneron, S. Nelson, R. Pieper, J. Phillips, S. Ronen, V. Clark, Z. E. Omay, A. Serin, J. Gunel, B. Omay, C. Grady, M. Youngblood, K. Bilguvar, J. Baehring, J. Piepmeier, P. Gutin, A. Vortmeyer, C. Brennan, M. N. Pamir, T. Kilic, B. Krischek, M. Simon, K. Yasuno, M. Gunel, A. L. Cohen, M. Sato, K. D. Aldape, C. Mason, K. Diefes, L. Heathcock, L. Abegglen, D. Shrieve, W. Couldwell, J. D. Schiffman, H. Colman, Q. G. D'Alessandris, T. Cenci, M. Martini, L. Ricci-Vitiani, R. De Maria, L. M. Larocca, R. Pallini, B. Theeler, F. Lang, G. Rao, M. Gilbert, E. Sulman, R. Luthra, K. Eterovic, M. Routbort, R. Verhaak, G. Mills, J. Mendelsohn, F. Meric-Bernstam, A. Yung, K. MacArthur, S. Hahn, G. Kao, R. Lustig, M. Alonso-Basanta, S. Chandrasekaran, E. P. Wileyto, E. Reyes, J. Dorsey, K. Fujii, K. Kurozumi, T. Ichikawa, M. Onishi, J. Ishida, Y. Shimazu, B. Kaur, E. A. Chiocca, I. Date, C. Geisenberger, A. Mock, R. Warta, C. Schwager, C. Hartmann, A. von Deimling, A. Abdollahi, C. Herold-Mende, O. Gevaert, A. Achrol, S. Gholamin, S. Mitra, E. Westbroek, J. Loya, L. Mitchell, S. Chang, G. Steinberg, S. Plevritis, S. Cheshier, J. Xu, S. Napel, G. Zaharchuk, G. Harsh, D. Gutman, C. Holder, R. Colen, W. Dunn, R. Jain, L. Cooper, S. Hwang, A. Flanders, D. Brat, J. Hayes, A. Droop, H. Thygesen, M. Boissinot, D. Westhead, S. Short, S. Lawler, P. Bady, S. Kurscheid, M. Delorenzi, M. E. Hegi, C. Crosby, C. Faulkner, T. Smye-Rumsby, K. Kurian, M. Williams, K. Hopkins, A. Palmer, H. Williams, C. Wragg, H. R. Haynes, K. M. Kurian, P. White, T. Oka, L. Jalbert, A. Elkhaled, R. Jensen, K. Salzman, M. Schabel, D. Gillespie, M. Mumert, B. Johnson, T. Mazor, M. Barnes, S. Yamamoto, H. Ueda, K. Tatsuno, K. Aihara, A. Bollen, M. Hirst, M. Marra, A. Mukasa, N. Saito, H. Aburatani, M. Berger, B. Taylor, S. Popov, A. Mackay, W. Ingram, A. Burford, A. Jury, M. Vinci, C. Jones, D. T. W. Jones, V. Hovestadt, S. Picelli, W. Wang, P. A. Northcott, M. Kool, G. Reifenberger, T. Pietsch, M. Sultan, H. Lehrach, M.-L. Yaspo, A. Borkhardt, P. Landgraf, R. Eils, A. Korshunov, M. Zapatka, B. Radlwimmer, S. M. Pfister, P. Lichter, A. Joy, I. Smirnov, M. Reiser, W. Shapiro, S. Kim, B. Feuerstein, C. Jungk, S. Friauf, A. Unterberg, T. A. Juratli, J. McElroy, W. Meng, A. Huebner, K. D. Geiger, D. Krex, G. Schackert, A. Chakravarti, T. Lautenschlaeger, B. Y. Kim, W. Jiang, J. Beiko, S. Prabhu, F. DeMonte, R. Sawaya, D. Cahill, I. McCutcheon, C. Lau, L. Wang, K. Terashima, S. Yamaguchi, M. Burstein, J. Sun, T. Suzuki, R. Nishikawa, H. Nakamura, A. Natsume, S. Terasaka, H.-K. Ng, D. Muzny, R. Gibbs, D. Wheeler, X.-q. Zhang, S. Sun, K.-f. Lam, K. M. Y. Kiang, J. K. S. Pu, A. S. W. Ho, G. K. K. Leung, F. Loebel, W. T. Curry, F. G. Barker, N. Lelic, A. S. Chi, D. P. Cahill, D. Lu, J. Yin, C. Teo, K. McDonald, A. Madhankumar, C. Weston, B. Slagle-Webb, J. Sheehan, A. Patel, M. Glantz, J. Connor, C. Maire, J. Francis, C.-Z. Zhang, J. Jung, V. Manzo, V. Adalsteinsson, H. Homer, B. Blumenstiel, C. S. Pedamallu, E. Nickerson, A. Ligon, C. Love, M. Meyerson, K. Ligon, L. E. Jalbert, S. J. Nelson, A. W. Bollen, I. V. Smirnov, J. S. Song, A. B. Olshen, M. S. Berger, S. M. Chang, B. S. Taylor, J. F. Costello, S. Mehta, B. Armstrong, S. Peng, A. Bapat, M. Berens, B. Melendez, M. Mollejo, P. Mur, T. Hernandez-Iglesias, C. Fiano, J. Ruiz, J. A. Rey, V. Stadler, A. Schulte, K. Lamszus, C. Schichor, M. Westphal, J.-C. Tonn, O. Morozova, S. Katzman, M. Grifford, S. Salama, D. Haussler, A. Olshen, S. Fouse, S. Nakamizo, T. Sasayama, H. Tanaka, K. Tanaka, K. Mizukawa, M. Yoshida, E. Kohmura, P. Northcott, D. Jones, S. Pfister, R. Otani, S. Takayanagi, K. Saito, S. Tanaka, M. Shin, T. Ozawa, M. Riester, Y.-K. Cheng, J. Huse, K. Helmy, N. Charles, M. Squatrito, F. Michor, E. Holland, M. Perrech, L. Dreher, G. Rohn, R. Goldbrunner, M. Timmer, B. Pollo, V. Palumbo, C. Calatozzolo, M. Patane, R. Nunziata, M. Farinotti, A. Silvani, S. Lodrini, G. Finocchiaro, E. Lopez, A. Rioscovian, R. Ruiz, G. Siordia, A. P. de Leon, C. Rostomily, R. Rostomily, D. Silbergeld, D. Kolstoe, M. Chamberlain, J. Silber, P. Roth, A. Keller, J. Hoheisel, P. Codo, A. Bauer, C. Backes, P. Leidinger, E. Meese, E. Thiel, A. Korfel, M. Weller, G. Nagae, M. Nagane, J. Z. Sanborn, T. Mikkelsen, S. Jhanwar, L. Chin, M. Nishihara, M. Schliesser, C. Grimm, E. Weiss, R. Claus, D. Weichenhan, M. Weiler, T. Hielscher, F. Sahm, B. Wiestler, A.-C. Klein, J. Blaes, C. Plass, W. Wick, G. Stragliotto, A. Rahbar, C. Soderberg-Naucler, M. Won, R. Ezhilarasan, P. Sun, D. Blumenthal, M. Vogelbaum, R. Jenkins, R. Jeraj, P. Brown, K. Jaeckle, D. Schiff, J. Dignam, J. Atkins, D. Brachman, M. Werner-Wasik, M. Mehta, J. Shen, J. Luan, A. Yu, M. Matsutani, Y. Liang, T.-K. Man, A. Trister, M. Tokita, S. Mikheeva, A. Mikheev, S. Friend, M. van den Bent, L. Erdem, T. Gorlia, M. Taphoorn, J. Kros, P. Wesseling, H. Dubbink, A. Ibdaih, P. French, H. van Thuijl, J. Heimans, B. Ylstra, J. Reijneveld, A. Prabowo, I. Scheinin, H. van Essen, W. Spliet, C. Ferrier, P. van Rijen, T. Veersema, M. Thom, A. S.-v. Meeteren, E. Aronica, H. Kim, S. Zheng, D. J. Brat, S. Virk, S. Amini, C. Sougnez, J. Barnholtz-Sloan, R. G. W. Verhaak, C. Watts, A. Sottoriva, I. Spiteri, S. Piccirillo, A. Touloumis, P. Collins, J. Marioni, C. Curtis, S. Tavare, B. Tews, T. P. C. Yeung, B. Al-Khazraji, L. Morrison, L. Hoffman, D. Jackson, T.-Y. Lee, S. Yartsev, G. Bauman, J. Fu, R. Vegesna, Y. Mao, L. E. Heathcock, W. Torres-Garcia, S. Wang, A. McKenna, C. W. Brennan, W. K. A. Yung, J. N. Weinstein, E. P. Sulman, and D. Koul

Subjects
Abstracts, Cancer Research, Text mining, Oncology, business.industry, Neurology (clinical), Computational biology, Biology, Omics, business
Published
2013

3. CLIN-NEURO-COGNITIVE

Author

J. L. Scotland, I. R. Whittle, I. J. Deary, E. K. De Witte, P. Marien, R. Jalali, V. Kothawade, T. Gupta, S. Goswami, J. Swamidas, C. A. Racine, J. M. Lupo, A. Molinaro, A. Parks, S. M. Chang, M. S. Berger, N. Butowski, C. Linville, R. Hampson, S. Deadwyler, A. Peiffer, K. B. Peters, S. Woodring, J. E. Herndon, F. McSherry, J. J. Vredenburgh, A. Desjardins, H. S. Friedman, J. S. Wefel, S. Shook, P. D. Brown, N. N. Laack, A. Choucair, J. H. Suh, D. Roberge, V. Kavadi, M. P. Mehta, D. Watkins-Bruner, C. Weiss, C. Nettekoven, V. Neuschmelting, A. Eisenbeis, A. Rehme, C. Grefkes, R. Goldbrunner, A. M. Peiffer, D. Case, E. G. Shaw, S. Rapp, S. Ambert-Pompey, N. D. Doolittle, C. Lacy, R. Fu, R. W. Butler, C. Varallyay, E. A. Neuwelt, A. Jakary, and S. J. Nelson

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Trail Making Test, Controlled Oral Word Association Test, Cognition, National Adult Reading Test, Abstracts, Cognitive epidemiology, Oncology, Cohort, Physical therapy, Medicine, Verbal fluency test, Neurology (clinical), business, Neurocognitive
Abstract

CLIN-NEURO-COGNITIVE NC-02. ASSESSING NEURO-COGNITIVE STATUS IN NEWLY PRESENTING PATIENTS WITH SUPRATENTORIAL INTRACRANIAL TUMOURS. Jennifer L. Scotland1, Ian R. Whittle1, and Ian J. Deary2; University of Edinburgh, Edinburgh, United Kingdom; Centre for Cognitive Ageing and Cognitive Epidemiology, Dept. of Psychology, University of Edinburgh, Edinburgh, United Kingdom INTRODUCTION: Neurocognitive endpoints are increasingly included in clinical trials in neuro-oncological settings (Meyers & Brown, 2006). There is a need to identify short, repeatable measures of cognition that are sensitive to impairment in this group. Previous authors have proposed such batteries. METHODS: Newly presenting patients with a radiological diagnosis of any intracranial tumour (n 1⁄4 118) were assessed, prior to any surgical intervention, on a number of standardised cognitive and other measures as part of a larger study (Scotland et al., 2012). Their performance was compared with that of patients admitted for elective spinal surgery (n 1⁄4 85) and a healthy control group (n 1⁄4 80). RESULTS: Analysis of covariance compared the performance of the three groups. Age, sex, and National Adult Reading Test score (used to assess premorbid function) were the covariates. Patients with intracranial tumours performed significantly worse on the majority of the tests. The intracranial tumour cohort had significantly lower scores than did the spinal surgery and healthy control groups on the following measures: immediate and delayed memory (Rey Auditory Verbal Learning Test, RAVLT; p , 0.001); Trail Making Test Part B (p , 0.001); digit-symbol coding (p , 0.001); and verbal fluency (Controlled Oral Word Association Test, COWAT; p 1⁄4 0.002 and p , 0.001, respectively). There was a moderate-to-large effect size in the participant group for all tests. DISCUSSION/CONCLUSIONS: The RAVLT, Trail Making Test Part B, and COWAT are sensitive measures of cognitive impairment in patients with brain tumours and support Meyers & Brown’s (2006) proposal for the inclusion of these tests in clinical trials that have neurocognitive endpoints. The verbal fluency test, in particular, has a number of potential advantages for use in neuro-oncological settings, given that it can be completed by patients with focal motor deficits and is available in alternate forms to reduce practice effects. NC-03. A STANDARD NEUROLINGUISTIC APPROACH TO

Published
2012

4. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Author

H. Pavel, N. Ajeawung, R. Faure, D. Poirier, D. Kamnasaran, H. Joshi, X. Lun, F. Zemp, B. Sun, O. Stechishin, A. Luchman, J. J. Kelly, S. Weiss, M. G. Hamilton, G. Cairncross, D. L. Senger, J. Bell, G. McFadden, P. A. Forsyth, S. Y. Tzeng, H. Guerrero-Cazares, E. E. Martinez, N. P. Young, J. C. Sunshine, A. Quinones-Hinojosa, J. J. Green, L. Lei, R. D'Amico, J. Sisti, R. Leung, A. M. Sonabend, P. Guarnieri, S. S. Rosenfeld, J. N. Bruce, P. Canoll, V. R. Baichwal, L. Reeves, B. L. Chad, K. H. Zavitz, A. P. Beelen, G. G. Mather, R. O. Carlson, C. Manton, J. Chandra, S. T. Keir, D. A. Reardon, J. R. Saling, L. S. Gray, D. D. Bigner, H. S. Friedman, J. Zhang, J. Brun, H. Ogbomo, Z. Wang, D. J. Stojdl, L.-Y. Kong, M. A. Hatiboglu, J. Wei, Y. Wang, K. A. McEnery, G. N. Fuller, W. Qiao, M. A. Davies, W. Priebe, A. B. Heimberger, B. Amendolara, O. Gil, S. Ivkovic, J. Bruce, S. Rosenfeld, S. Finniss, B. Perlstein, C. Miller, H. Okhrimenko, G. Kazimirsky, S. Cazacu, N. Lemke, S. Brodie, S. A. Rempel, M. Rosenblum, T. Mikkelsen, S. Margel, C. Brodie, H. Guvenc, H. Demir, S. Gupta, S. Mazumder, A. Ray-Chaundhury, T. Li, C. Li, I. Nakano, R. Rahman, C. Rahman, S. Smith, D. Macarthur, F. Rose, K. Shakesheff, R. G. Grundy, A. J. Brenner, B. Goins, A. Bao, J. Miller, A. Trevino, R. Zuniga, W. T. Phillips, A. G. Gilg, K. G. Bowers, B. P. Toole, B. L. Maria, G. K. Leung, S. Sun, S. T. Wong, X. Q. Zhang, J. K. Pu, W. M. Lui, A. M. Marino, I. M. Hussaini, S. Amos, K. Simpson, G. T. Redpath, C. Lyons, C. Dipierro, G. A. Grant, C. Wilson, S. Salami, P. Macaroni, S. Li, J.-Y. Park, D. Needham, D. Bigner, M. Dewhirst, J. Ohlfest, J. Gallardo, S. Argawal, R. Mittapalli, R. Donelson, W. F. Elmquist, T. Nicolaides, S. Hariono, K. Barkovich, R. Hashizume, D. Rowitch, W. Weiss, D. Sheer, S. Baker, B. Paugh, T. Waldman, H. Li, C. Jones, T. Forshew, D. James, H. Caroline, R. Patrick, L. Katrin, F. Karl, T. Ghazaleh, W. Michael, V. Albrecht, J. Thorsteinsdottir, E. Wagner, J.-C. Tonn, M. Ogris, C. Schichor, G. Charest, B. Paquette, L. Sanche, D. Mathieu, D. Fortin, X. Qi, F. Cuttitta, Z. Chu, J. Celerier, J. Pakradouni, O. Rixe, A. Gragg, S. Muller, A. Banerjee, J. Phillips, M. Prados, D. Haas-Kogan, N. Gupta, L. Florence, V. G. Gwendoline, M. Veronique, K. Robert, S. Agarwal, R. K. Mittapalli, L. Cen, B. L. Carlson, J. N. Sarkaria, S. Sengupta, S. D. Weeraratne, S. Rallapalli, V. Amani, J. Pierre-Francois, N. Teider, A. Rotenberg, J. Cook, S. L. Pomeroy, F. Jenses, Y.-J. Cho, M. Hjouj, D. Last, D. Guez, D. Daniels, J. Lavee, B. Rubinsky, Y. Mardor, L. P. Serwer, C. O. Noble, K. Michaud, D. C. Drummond, T. Ozawa, Y. Zhou, J. D. Marks, K. Bankiewicz, J. W. Park, W. Wang, H. Cho, M. Weintraub, N. Jhaveri, S. Torres, N. Petasis, A. H. Schonthal, S. G. Louie, F. M. Hofman, T. C. Chen, Z. Grada, M. Hegde, D. R. Schaffer, A. Ghazi, T. Byrd, G. Dotti, W. Wels, H. E. Heslop, S. Gottschalk, M. Baker, N. Ahmed, K. J. Hamblett, C. J. Kozlosky, H. Liu, S. Siu, T. Arora, M. W. Retter, K. Matsuda, J. S. Hill, W. C. Fanslow, R. J. Diaz, A. Etame, O. Meaghan, T. Mainprize, C. Smith, K. Hynynen, J. Rutka, J. Pradarelli, J. Y. Yoo, A. Kaka, C. Alvarez-Breckenridge, Q. Pan, E. A. Chiocca, T. Teknos, B. Kaur, S. Y. Lee, B. Slagle-Webb, J. M. Sheehan, J. R. Connor, J. Cote, M. Lepage, F. Gobeil, A. Kleijn, R. Balvers, J. Kloezeman, C. Dirven, M. Lamfers, S. Leenstra, W. See, I.-L. Tan, R. Pieper, H. Jiang, E. White, C. I. Rios-Vicil, W.-K. A. Yung, C. Gomez-Manzano, J. Fueyo, F. J. Zemp, B. A. McKenzie, S. Mueller, X. Yang, I. Smirnov, D. C. James, J. J. Phillips, M. S. Berger, D. H. Rowitch, D. H. Haas-Kogan, B. Kennedy, V. Gopalakrishnan, C. Das, P. Taylor, R. Kommagani, X. Su, D. Aguilera, A. Thomas, J. Wolff, E. Flores, M. Kadakia, R. Alkins, P. Broderson, R. Sodhi, S. A. Chung, K. L. McDonald, H. Shen, B. W. Day, B. W. Stringer, T. Johns, S. Decollogne, C. Teo, P. J. Hogg, P. J. Dilda, T. R. Patel, J. Zhou, J. M. Piepmeier, W. M. Saltzman, M. A. Vogelbaum, P. Manchanda, J. R. Ohlfest, G. J. Kitange, A. C. Mladek, M. A. Schroeder, J. L. Pokorny, C. Mody, P. Forsyth, T. Dasgupta, C. D. James, A. B. Madhankumar, B. S. Webb, A. Park, K. Harbaugh, and J. Sheehan

Subjects
Abstracts, Cancer Research, Oncology, business.industry, Medicine, Neurology (clinical), Pharmacology, business
Abstract

The 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, Orange County, California, USA, 17-20 November 2011. In Neuro-Oncology, 2011, v. 13 n. Suppl. 3, p. iii111, abstract no. ET-18

Published
2011

5. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

Author

F R Appelbaum, C Karanes, E. H. Estey, I D Bernstein, C B Eten, J J M Van Dongen, J M Bennett, Marc Boogaerts, Michael R. Loken, P Mineur, E L Sievers, Edward A. Stadtmauer, M Munteanu, M S Berger, and Richard A. Larson

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Gemtuzumab ozogamicin, medicine.medical_treatment, Sialic Acid Binding Ig-like Lectin 3, CD33, Antigens, Differentiation, Myelomonocytic, Neutropenia, Antibodies, Monoclonal, Humanized, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Antigens, CD, Internal medicine, Calicheamicin, medicine, Mucositis, Humans, Survival rate, Aged, Monitoring, Physiologic, Aged, 80 and over, Chemotherapy, business.industry, Immunotoxins, Antibodies, Monoclonal, Myeloid leukemia, Hematology, Middle Aged, Prognosis, medicine.disease, Gemtuzumab, Anti-Bacterial Agents, Surgery, Survival Rate, Aminoglycosides, Oncology, chemistry, Leukemia, Myeloid, Acute Disease, Female, Neoplasm Recurrence, Local, business, medicine.drug
Abstract

We analyzed the safety and efficacy of Mylotarg (gemtuzumab ozogamicin, an antibody-targeted chemotherapy consisting of a humanized anti-CD33 antibody linked to calicheamicin, a potent antitumor antibiotic) in the treatment of 101 patients > or =60 years of age with acute myeloid leukemia (AML) in untreated first relapse in three open-label trials. Mylotarg is administered as a 2-h intravenous infusion at 9 mg/m(2) for two doses with 14 days between doses. The overall remission rate was 28%, with complete remission (CR) in 13% of patients and complete remission with incomplete platelet recovery (CRp) in 15%. Median survival was 5.4 months for all patients and 14.5 months and 11.8 months for patients achieving CR and CRp, respectively. CD33 antigen is present on normal hematopoietic progenitor cells; thus, an expected high incidence of grade 3 or 4 neutropenia (99%) and thrombocytopenia (99%) was observed. The incidences of grade 3 or 4 elevations of bilirubin and hepatic transaminases were 24% and 15%, respectively. There was a low incidence of grade 3 or 4 mucositis (4%) and infections (27%) and no treatment-related cardiotoxicity, cerebellar toxicity, or alopecia. Mylotarg is an effective treatment for older patients with CD33-positive AML in first relapse and has acceptable toxicity.

Published
2002

6. Predicting disease progression in childhood cerebellar astrocytoma

Author

M S Berger, J R Geyer, D M Lieberman, and D W Smoots

Subjects
Male, Pathology, medicine.medical_specialty, Adolescent, Astrocytoma, Ventriculoperitoneal Shunt, Central nervous system disease, Glioma, medicine, Humans, Neurofibromatosis, Cerebellar Neoplasms, Child, medicine.diagnostic_test, business.industry, Childhood Cerebellar Astrocytoma, Infant, Magnetic resonance imaging, Cerebellar Neoplasm, General Medicine, Prognosis, medicine.disease, Survival Analysis, Child, Preschool, Multivariate Analysis, Pediatrics, Perinatology and Child Health, Disease Progression, Female, Neurology (clinical), Neurosurgery, Neoplasm Recurrence, Local, Tomography, X-Ray Computed, business, Hydrocephalus
Abstract

Pediatric cerebellar astrocytomas are frequently curable by complete surgical resection. However, even incompletely resected tumors may lie dormant indefinitely or spontaneously involute, and tumors thought to be completely excised have reappeared in the same location several years later. Because of the unpredictable nature of some cerebellar astrocytomas, this study was designed to analyze several variables for their potential value in predicting disease progression. The charts of 78 children treated at a children's hospital between 1966 and 1993 were reviewed; 62 tumors were pilocytic, 13 were fibrillary, and 3 were mixed oligoastrocytomas. Four children had the additional diagnosis of neurofibromatosis type 1, and those children were considered separately. Of the remaining 74 children, 48 underwent postoperative contrast-enhanced computerized tomography or magnetic resonance imaging. Of those 48 children, 17 had residual disease, and in 15 cases the tumor volume could be measured. Frequently the surgeon's report conflicted with the postoperative scan regarding the presence of residual disease. However, the surgeon's report of brainstem infiltration correlated highly with residual disease on postoperative imaging. On univariate Cox analysis, sex, age, tumor location, and tumor morphology did not show prognostic significance. In spite of their differences, the surgeon's report of residual tumor and the presence of residual disease on postoperative imaging were similar in their correlation with disease progression. However, on multivariate analysis, the volume of residual tumor was most closely linked with disease progression. Only the presence of fibrillary histology significantly complemented the volume of residual tumor as a negative prognostic indicator.

Published
1998

7. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

Author

M. M. Moezi, J. Schnyder, Alberto Chiappori, M S Berger, M. T. Schreeder, J. Stephenson, Deepa S. Subramaniam, J. L. Blakely, Ravi Salgia, Helen J. Ross, and Q. S. Chu

Subjects
Central Nervous System, Male, Cancer Research, Indoles, Lung Neoplasms, Maximum Tolerated Dose, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Pharmacology, Drug Administration Schedule, Bcl-2 gene family, Carboplatin, chemistry.chemical_compound, Clinical Research, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, In patient, Pyrroles, Oncology & Carcinogenesis, Lung, Etoposide, Cancer, Aged, business.industry, Lung Cancer, Antagonist, apoptosis, Hematology, Middle Aged, Small Cell Lung Carcinoma, Oncology, chemistry, Proto-Oncogene Proteins c-bcl-2, Apoptosis, 6.1 Pharmaceuticals, Public Health and Health Services, Clinical Study, Female, Patient Safety, small cell lung cancer, business, Extensive-stage small cell lung cancer, CNS symptoms, Obatoclax, medicine.drug
Abstract

Background: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. Methods: Eligible patients (3–6 per cohort) had extensive-stage SCLC, measurable disease, ⩽1 before therapy, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients were treated with escalating doses of obatoclax, either as a 3- or 24-h infusion, on days 1–3 of a 21-day cycle, in combination with carboplatin (area under the curve 5, day 1 only) and etoposide (100 mg m−2, days 1–3). The primary endpoint was to determine the maximum tolerated dose of obatoclax. Results: Twenty-five patients (56% male; median age 66 years) were enrolled in three dose cohorts for each schedule. Maximum tolerated dose was established with the 3-h infusion at 30 mg per day and was not reached with the 24-h infusion. Compared with the 24-h cohorts, the 3-h cohorts had higher incidence of central nervous system (CNS) adverse events (AEs); dose-limiting toxicities were somnolence, euphoria, and disorientation. These CNS AEs were transient, resolving shortly after the end of infusion, and without sequelae. The response rate was 81% in the 3-h and 44% in the 24-h infusion cohorts. Conclusion: Although associated with a higher incidence of transient CNS AEs than the 24-h infusion, 3-h obatoclax infusion combined with carboplatin–etoposide was generally well tolerated at doses of 30 mg per day. Though patient numbers were small, there was a suggestion of improved efficacy in the 3-h infusion group. Obatoclax 30 mg infused intravenously over 3 h on 3 consecutive days will be utilised in future SCLC studies.

Published
2012

8. MEDICAL AND NEURO-ONCOLOGY

Author

G. K. Prithviraj, S. R. Sommers, R. L. Jump, B. Halmos, L. B. Chambless, S. L. Parker, L. Hassam-Malani, M. J. McGirt, R. C. Thompson, K. Hunter, M. C. Chamberlain, E. M. Le, E. L. T. Lee, Z. S. Sadighi, M. L. Pearlman, J. M. Slopis, T. S. Vats, S. Khatua, N. C. DeVito, M. Yu, R. Chen, E. Pan, T. Cloughesy, J. Raizer, J. Drappatz, M. Gerena-Lewis, J. Rogerio, S. Yacoub, A. Desjardin, M. D. Groves, J. DeGroot, M. Loghin, C. A. Conrad, K. Hess, J. Ni, S. Ictech, W. A. Yung, A. B. Porter, A. C. Dueck, N. J. Karlin, J. Olson, J. Silber, A. S. Reiner, K. S. Panageas, F. M. Iwamoto, T. F. Cloughesy, K. D. Aldape, A. L. Rivera, A. F. Eichler, D. N. Louis, N. A. Paleologos, B. J. Fisher, L. S. Ashby, J. G. Cairncross, G. B. Roldan, P. Y. Wen, K. L. Ligon, D. Shiff, H. I. Robins, B. G. Rocque, W. P. Mason, S. A. Weaver, R. M. Green, F. G. Kamar, L. E. Abrey, L. M. DeAngelis, S. C. Jhanwar, M. K. Rosenblum, A. B. Lassman, D. Cachia, L. Alderson, R. Moser, T. Smith, S. Yunus, K. Saito, A. Mukasa, Y. Narita, Y. Tabei, N. Shinoura, S. Shibui, N. Saito, B. Flechl, M. Ackerl, C. Sax, K. Dieckmann, R. Crevenna, G. Widhalm, M. Preusser, C. Marosi, C. Ay, D. Dunkler, I. Pabinger, C. Zielinski, M. Belongia, S. Jogal, K.-H. Schlingensiepen, U. Bogdahn, G. Stockhammer, A. K. Mahapatra, N. K. Venkataramana, V. Oliushine, V. Parfenov, I. Poverennova, P. Hau, P. Jachimczak, H. Heinrichs, A. G. Mammoser, N. A. Shonka, J. F. de Groot, I. Shibahara, Y. Sonoda, T. Kumabe, R. Saito, M. Kanamori, Y. Yamashita, M. Watanabe, C. Ishioka, T. Tominaga, A. Silvani, P. Gaviani, E. Lamperti, A. Botturi, F. DiMeco, G. Broggi, L. Fariselli, C. L. Solero, A. Salmaggi, E. A. Woyshner, F. Shu, Y. S. Oh, S. Iganej, G. Singh, S. L. Vemuri, B. J. Theeler, B. Ellezam, M. R. Gilbert, T. Aoki, H. Kobayashi, S. Takano, R. Nishikawa, M. Nagane, Y. Muragaki, K. Sugiyama, J. Kuratsu, M. Matsutani, L. A. Langford, V. K. Puduvalli, D. Shen, Z.-p. Chen, J.-p. Zhang, D. Bedekar, S. Rand, J. Connelly, M. Malkin, E. Paulson, W. Mueller, K. Schmainda, O. Gallego, M. Benavides, P. P. Segura, C. Balana, M. Gil, A. Berrocal, G. Reynes, J. L. Garcia, P. Murata, S. Bague, M. J. Quintana, V. G. Vasishta, K. Kobayashi, M. Tanaka, K. Tsuchiya, Y. Shiokawa, A. A. Bavle, K. Ayyanar, M. P. Prado, K. R. Hess, V. Liu, J. de Groot, M. E. Loghin, H. Colman, V. A. Levin, W. K. Alfred Yung, J. R. Hackney, C. A. Palmer, J. M. Markert, J. Cure, K. O. Riley, H. Fathallah-Shaykh, L. B. Nabors, M. G. Saria, C. Corle, J. Hu, J. Rudnick, S. Phuphanich, M. M. Mrugala, L. K. Lee, B. D. Fu, D. A. Bota, R. Y. Kim, T. Brown, H. Feely, A. Hu, J. W. Lee, B. Carter, S. Kesari, X.-T. Kong, S. Sparagana, E. Belousova, S. Jozwiak, B. Korf, M. Frost, R. Kuperman, M. Kohrman, O. Witt, J. Wu, R. Flamini, A. Jansen, P. Curtalolo, E. Thiele, V. Whittemore, P. De Vries, J. Ford, G. Shah, H. Cauwel, P. Edrich, T. Sahmoud, D. Franz, M. Khasraw, C. Brown, D. M. Ashley, M. A. Rosenthal, X. Jiang, Y. g. Mou, Z. p. Chen, M. Oh, E. kim, J. Chang, T. A. Juratli, M. Kirsch, G. Schackert, D. Krex, M. Wang, R. Stupp, M. Hegi, K. A. Jaeckle, T. S. Armstrong, J. S. Wefel, M. Won, D. T. Blumenthal, A. Mahajan, C. J. Schultz, S. C. Erridge, P. D. Brown, A. Chakravarti, W. J. Curran, M. P. Mehta, K. F. Hofland, S. Hansen, M. Sorensen, H. Schultz, A. Muhic, S. Engelholm, A. Ask, C. Kristiansen, C. Thomsen, H. S. Poulsen, U. N. Lassen, O. Zalatimo, C. Weston, C. Zoccoli, M. Glantz, S. Rahmanuddin, M. S. Shiroishi, S. Y. Cen, J. Jones, T. Chen, P. Pagnini, J. Go, A. Lerner, J. Gomez, M. Law, Z. Ram, E. T. Wong, P. H. Gutin, M. S. Bobola, M. Alnoor, D. L. Silbergeld, R. C. Rostomily, J. R. Silber, N. Martha, S. Jacqueline, G. Thaddaus, P. Daniel, M. Hans, M. Armin, T. Eugen, S. Gunther, M. Hutterer, H.-M. Tseng, C. M. Zoccoli, A. Patel, K. Rizzo, J. M. Sheehan, A. L. Sumrall, J. J. Vredenburgh, A. Desjardins, D. A. Reardon, H. S. Friiedman, K. B. Peters, L. P. Taylor, M. Stewart, N. A. Blondin, J. M. Baehring, T. Foote, N. Laack, J. Call, M. G. Hamilton, S. Walling, M. Eliasziw, J. Easaw, N. V. Shirsat, R. Kundar, A. Gokhale, A. Goel, A. A. Moiyadi, J. Wang, E. Mutlu, A. Oyan, T. Yan, O. Tsinkalovsky, H. K. Jacobsen, K. M. Talasila, L. Sleire, K. Pettersen, H. Miletic, S. Andersen, S. Mitra, I. Weissman, X. Li, K.-H. Kalland, P. O. Enger, J. Sepulveda, C. Belda, R. Sitt, L. Phishniak, F. Bokstein, M. Philippe, C. Carole, M. d. P. Andre, B. Marylin, C. Olivier, O. L'Houcine, F.-B. Dominique, N.-M. Isabelle, F. Frederic, F. Stephane, D. Henry, M. A. Errico, L. J. Kunschner, R. Soffietti, E. Trevisan, R. Ruda, L. Bertero, C. Bosa, M. G. Fabrini, I. Lolli, R. Jalali, P. K. Julka, A. K. Anand, D. Bhavsar, N. Singhal, R. Naik, S. John, B. S. Mathew, I. Thaipisuttikul, J. Graber, M. Shirinian, A. M. Fontebasso, K. Jacob, N. Gerges, A. Montpetit, A. Nantel, S. Albrecht, N. Jabado, K. Shah, K. Di, M. Linskey, N. Thon, S. Eigenbrod, S. Kreth, J. Lutz, J.-C. Tonn, H. Kretzschmar, A. Peraud, F.-W. Kreth, A. D. Muggeri, J. P. Alderuccio, B. D. Diez, P. Jiang, Y. Chao, M. Gallagher, R. Kim, S. Pastorino, V. Fogal, J. D. Rudnick, C. Bresee, A. Rogatko, S. Sakowsky, M. Franco, S. Lim, A. Lopez, L. Yu, K. Ryback, V. Tsang, M. Lill, A. Steinberg, R. Sheth, S. Grimm, I. Helenowski, A. Rademaker, F. P. Nunes, V. Merker, D. Jennings, P. Caruso, A. Muzikansky, A. Stemmer-Rachamimov, S. Plotkin, A. C. Spalding, T. W. Vitaz, D. A. Sun, S. Parsons, M. R. Welch, A. Omuro, K. Beal, D. Correa, T. Chan, L. DeAngelis, I. Gavrilovic, C. Nolan, A. Hormigo, T. Kaley, I. Mellinghoff, C. Grommes, K. Panageas, A. Reiner, R. Barradas, L. Abrey, P. Gutin, S. Y. Lee, B. Slagle-Webb, M. J. Glantz, J. R. Connor, C. A. Schlimper, H. Schlag, G. Stoffels, F. Weber, D. A. Krueger, M. M. Care, K. Holland, K. Agricola, C. Tudor, A. Byars, D. N. Franz, L. Rice, J. Chandler, R. Levy, K. Muro, L. Nayak, A. D. Norden, T. J. Kaley, A. A. Thomas, C. E. Fadul, L. P. Meyer, E. C. Lallana, M. Gilbert, K. Aldape, J. De Groot, C. Conrad, V. Levin, M. Groves, P. Chris, V. Puduvalli, S. Nagpal, A. Feroze, L. Recht, H. G. Rangarajan, M. W. Kieran, R. M. Scott, S. M. Lew, S. Y. Firat, A. D. Segura, S. A. Jogal, P. U. Kumthekar, S. A. Grimm, M. Avram, J. Patel, V. Kaklamani, K. McCarthy, M. Cianfrocca, W. Gradishar, M. Mulcahy, J. Von Roenn, E. Galanis, S. K. Anderson, J. M. Lafky, T. J. Kaufmann, J. H. Uhm, C. Giannini, S. K. Kumar, D. W. Northfelt, P. J. Flynn, J. C. Buckner, A. I. Omar, D. Schiff, A. Delios, A. Jakubowski, I. Melguizo-Gavilanes, W. Qiao, X. Wang, N. Hashemi-Sadraei, H. Bawa, G. Rahmathulla, M. Patel, P. Elson, G. Stevens, D. Peereboom, M. Vogelbaum, R. Weil, G. Barnett, M. S. Ahluwalia, E. C. Alvord, R. C. Rockne, J. K. Rockhill, R. Rostomily, A. Lai, J. Wardlaw, A. M. Spence, K. R. Swanson, G. Zadeh, H. Alahmadi, J. Wilson, F. Gentili, J. J. Beumer, J. Wright, N. Takebe, R. Gaur, M. Werner-Wasik, A. J. Gupta, A. Campos-Gines, K. Le, C. Arango, M. Richards, M. Landeros, H. Juan, J. H. Chang, J. S. Kim, J. H. Cho, C. O. Seo, A. L. Baldock, R. Rockne, P. Canoll, D. Born, K. Yagle, D. Alexandru, D. Bota, M. E. Linskey, S. Nabeel, S. N. Raval, J. Rosenow, M. Bredel, P. Z. New, S. R. Plotkin, J. G. Supko, W. T. Curry, A. S. Chi, E. R. Gerstner, T. T. Batchelor, N. Hashemi, S. T. Chao, R. J. Weil, J. H. Suh, M. A. Vogelbaum, G. H. Stevens, G. H. Barnett, D. Corwin, C. Holdsworth, R. Stewart, K. Swanson, J. J. Graber, A. R. Anderson, S. Jeyapalan, M. Goldman, J. Boxerman, J. Donahue, H. Elinzano, D. Evans, B. O'Connor, M. Y. Puthawala, A. Oyelese, D. Cielo, M. Blitstein, M. Dargush, A. Santaniello, M. Constantinou, T. DiPetrillo, H. Safran, C. Halpin, F. G. Barker, E. A. Maher, S. Ganji, R. DeBerardinis, K. Hatanpaa, D. Rakheja, X.-L. Yang, T. Mashimo, J. Raisanen, C. Madden, B. Mickey, C. Malloy, R. Bachoo, C. Choi, T. Ranjan, N. Yono, S. J. Han, M. Sun, M. S. Berger, M. Aghi, N. Gupta, and A. T. Parsa

Subjects
Cancer Research, medicine.medical_specialty, Abstracts, Oncology, business.industry, Neuro oncology, medicine, Medical physics, Neurology (clinical), business
Published
2011

9. OMICS AND PROGNOSTIC MARKERS

Author

F. Moriera, K. So, P. Gould, D. Kamnasaran, R. L. Jensen, I. Hussain, D. H. Gutmann, D. Gorovets, E. R. Kastenhuber, E. Pentsova, L. Nayak, J. T. Huse, M. J. van den Bent, L. A. Gravendeel, T. Gorlia, J. M. Kros, P. Wesseling, J. Teepen, A. Idbaih, M. Sanson, P. A. S. Smitt, P. J. French, W. Zhang, J. Zhang, K. Hoadley, B. Carter, S. Li, C. Kang, Y. You, C. Jiang, S. Song, T. Jiang, C. Chen, C. Grimm, M. Weiler, R. Claus, D. Weichenhan, C. Hartmann, C. Plass, M. Weller, W. Wick, R. B. Jenkins, H. Sicotte, Y. Xiao, B. L. Fridley, P. A. Decker, M. L. Kosel, T. M. Kollmeyer, S. R. Fink, A. L. Rynearson, T. Rice, L. S. McCoy, I. Smirnov, T. Tehan, H. M. Hansen, J. S. Patoka, M. D. Prados, S. M. Chang, M. S. Berger, D. H. Lachance, J. K. Wiencke, J. L. Wiemels, M. R. Wrensch, M. H. Gephart, E. Lee, S. Kyriazopoulou-Panagiotopoulou, L. Milenkovic, X. Xun, Y. Hou, W. Kui, M. Edwards, S. Batzoglou, W. Jun, M. Scott, J. E. Hobbs, J. Tipton, T. Zhou, N. L. Kelleher, J. P. Chandler, J. Schwarzenberg, J. Czernin, T. Cloughesy, B. Ellingson, C. Geist, M. Phelps, W. Chen, M. Nakada, Y. Hayashi, W. Obuchi, S. Ohtsuki, T. Watanabe, C. Ikeda, K. Misaki, D. Kita, N. Uchiyama, T. Terasaki, J.-i. Hamada, L. Hiddingh, B. Tops, E. Hulleman, G.-J. L. Kaspers, W. P. Vandertop, D. P. Noske, T. Wurdinger, J. W. Jeuken, A. P. See, T. Hwang, D. Shin, J. H. Shin, Y. Gao, M. Lim, M. Hutterer, M. Michael, U. Gerold, S. Karin, G. Ingrid, D. Florian, M. Armin, T. Eugen, G. Eberhard, S. Gunther, R. W. Cook, K. Oelschlager, H. Sevim, L. Chung, H. T. Wheeler, R. C. Baxter, K. L. McDonald, A. Chaturbedi, L. Yu, Y.-H. Zhou, A. Wong, R. Fatuyi, M. E. Linskey, I. Lavon, T. Shahar, D. Zrihan, A. Granit, Z. Ram, T. Siegal, D. J. Brat, L. A. Cooper, D. A. Gutman, C. S. Chisolm, C. Appin, J. Kong, T. Kurc, E. G. Van Meir, J. H. Saltz, C. S. Moreno, H. J. Abuhusain, A. S. Don, R. P. Nagarajan, B. E. Johnson, A. B. Olshen, M. Xie, J. Wang, V. Sundaram, P. Paris, T. Wang, J. F. Costello, A. E. Sijben, S. H. Boots-Sprenger, J. Boogaarts, J. Rijntjes, J. M. Geitenbeek, J. van der Palen, H. J. Bernsen, O. Schnell, S. A. Adam, S. Eigenbrod, H. A. Kretzschmar, J.-C. Tonn, U. Schuller, P. W. Sperduto, N. Kased, D. Roberge, Z. Xu, R. Shanley, X. Luo, P. K. Sneed, S. T. Chao, R. J. Weil, J. Suh, A. Bhatt, A. W. Jensen, P. D. Brown, H. A. Shih, J. Kirkpatrick, L. E. Gaspar, J. B. Fiveash, V. Chiang, J. P. Knisely, C. M. Sperduto, N. Lin, M. P. Mehta, M. M. Kwatra, T. M. Porter, K. E. Brown, J. E. Herndon, D. D. Bigner, R. H. Dahlrot, B. W. Kristensen, S. Hansen, E. P. Sulman, D. P. Cahill, M. Wang, M. Won, M. E. Hegi, K. D. Aldape, M. R. Gilbert, E. S. Sadr, A. Tessier, M. S. Sadr, J. Alshami, C. Sabau, R. Del Maestro, M. L. Neal, R. Rockne, A. D. Trister, K. R. Swanson, S. Maleki, M. Back, M. Buckland, D. Brazier, K. McDonald, R. Cook, N. Parker, H. Wheeler, L. Jalbert, A. Elkhaled, J. J. Phillips, H. A. Yoshihara, R. Parvataneni, R. Srinivasan, G. Bourne, S. Cha, S. J. Nelson, M. Gilbert, D. Cahill, M. Hegi, H. Colman, M. Mehta, E. Sulman, A. Constantin, J. Phillips, H. Yoshihara, S. Nelson, S. Gunn, X. T. Reveles, B. Tirtorahardjo, M. N. Strecker, and L. Fichtel

Subjects
Cancer Research, Abstracts, Text mining, Oncology, business.industry, Medicine, Neurology (clinical), Computational biology, business, Omics
Published
2011

10. Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy

Author

Tore G. Abrahamsen, Finn Wesenberg, Sverre Mørk, Jeffrey Allen, Roberta Hayes, Robert DaRosso, Anita Nirenberg, Francis Ali-Osman, Nike Akande, V. Amberger, H. Seulberger, P. A. Paganetti, M. E. Schwab, N. Arita, T. Ohnishi, S. Hiraga, H. Yamamoto, T. Taki, S. Izumoto, M. Higuchi, T. Hayakawa, M. Kusakabe, T. Sakakura, N. G. Baldwin, C. D. Rice, R. E. Merchant, Sally M. Ashmore, J. L. Darling, C. C. Bailey, C. Balmaceda, B. Diez, J. Villablanca, R. Walker, J. Finlay, A. Tommy Bergenheim, Magdalena Hartman, Jonas Bergh, PerÅke Ridderheim, Roger Henriksson, Michael E. Berens, Monique D. Rief, Alf Giese, Björn Zackrisson, Jörgen Elfversson, Mark Bernstein, Alberto Cabantog, Jennifer Glen, David Mikulis, Rolf Bjerkvig, Paal-Henning Pedersen, Berit Mathisen, Rupavathana Mahesparan, Hans Kristian Haugland, Normand Laperriere, Cindy Thomason, Phil Leung, M. S. Bobola, M. S. Berger, J. R. Silber, Erik Bongcam-Rudloff, Jia-Lun Wang, Monica Nistér, Bengt Westermark, Steven Brem, Gary Breslow, Jason Ho, Stephen Gately, Shingo Takano, William Ward, M. Brada, R. Laing, J. Warrington, Herbert Engelhard, Barry Landau, Hau Kwaan, Elaine Verrusio, J. C. Buckner, T. L. Cascino, P. S. Schomberg, J. R. O'Fallon, R. P. Dinapoli, P. A. Burch, E. G. Shaw, William C. Broaddus, Kathryn Hager-Loudon, Randall E. Merchant, William Loudon, William T. Couldwell, Jack B. Jiang, David Burns, Martin H. Weiss, Michael L. J. Apuzzo, I. Desbaillets, M. Tada, N. de Tribolet, E. Van Meir, R. L. Davis, K. Onda, M. D. Prados, M. Eileen Dolan, Matthew J. Fleig, Henry S. Friedman, A. Jonas Ekstrand, Nicola Longo, C. David James, D. Chou, B. Wijnhoven, M. Bellinzona, M. Nakagawa, B. G. Feuerstein, H. S. Basu, M. E. Dolan, C. Bergeron, M. Pellarm, D. F. Deen, L. J. Marton, Jonathan Finlay, D. S. Fulton, R. C. Urtasun, Adrienne C. Scheck, J. Geddes, G. M. Vowles, S. M. Ashmore, G. Y. Gillespie, C. K. Goldman, M. T. Tucker, E. Lyon, J. -C. Tsai, G. T. Gobbel, P. H. Chan, Hairy S. Greenberg, W. F. Chandler, W. D. Ensminger, L. Junck, H. Sandler, J. Bromberg, P. McKeever, G. G. Gonzalez, A. Sarkar, H. Basu, Kr. Haugland, Ole-Bjørn Tysnes, Shoju Hiraga, Norio Arita, Takanori Ohnishi, Takuyu Taki, Hiroshi Yamamoto, Masahide Higuchi, Toru Hayakawa, Erik Isern, Geirmund Unsgaard, Anne Beate Langeland Marthinsen, Trond Strickert, Eirik Helseth, F. Hochberg, R. Cosgrove, R. Valenzuela, F. Pardo, N. Zervas, Robert B. Jenkins, Steven R. Ritland, Kevin C. Hailing, Stephen N. Thibodeau, L. Juillerat, P. Darekar, R. C. Janzer, M. F. Hamou, Tsutomu Kato, Yutaka Sawamura, Mitsuhiro Tada, Shirou Sakuma, Masako Sudo, Hiroshi Abe, M. Kallio, J. Leppää, T. Nikula, P. Nikkinen, H. Gylling, M. Färkkilä, J. Hiltunen, J. Jääskeläinen, K. Liewendahl, G. Evren Keles, Mitchel S. Berger, Anna Deliganis, S. J. Kellie, S. S. N. De Graaf, H. Bloemhof, I. Johnston, D. D. R. Uges, M. Besser, R. W. Chaseling, R. A. Ouvrier, N. D. Kitchen, S. Hughes, R. Beaney, D. G. T. Thomas, D. H. Kim, T. Maeda, G. Mohapatra, S. Park, F. W. Waldman, J. W. Gray, D. Koala, J. Silber, M. Berger, P. Krauseneck, B. Müller, H. Strik, M. Warmuth-Metz, Jun-ichi Kuratsu, Hideo Takeshima, Yukitaka Ushio, C. Kretschmar, H. Grodman, R. Linggood, A. P. Kyritsis, M. Bondy, J. Cunningham, M. Xiao, V. Levin, N. Leeds, J. Bruner, W. K. A. Yung, H. Saya, L. A. Lampson, M. R. Nichols, M. A. Lampson, A. D. Dunne, Hong Li, Marie-France Hamou, Rehana Jaufeerally, Annie-Claire Diserens, Erwin Van Meir, Nicolas de Tribolet, V. A. Levin, M. Maor, R. Sawaya, M. Leavens, S. Woo, P. Thall, M. J. Gleason, Bertrand C. Liang, D. A. Ross, P. S. Meltzer, J. M. Trent, H. S. Greenberg, K. O. Lillehei, Q. Kong, B. K. DeMasters, S. J. Withrow, D. R. Macdonald, J. G. Cairncross, S. Ludwin, D. Lee, T. Cascino, J. Buckner, E. Dropcho, D. Fulton, D. Stewart, C. Schold, N. Wainman, E. Eisenhauer, S. Kirby, B. J. Fisher, L. Magrassi, G. Butti, S. Pezzotta, G. Milanesi∘, Masao Matsutani, Kirsten Marienhagen, Ole Didrik Laerum, Abderrahim Merzak, Shahriar Koocheckpour, Yannis Roxanis, Geoffrey J. Pilktngton, Masakatsu Nagai, Kunihiko Watanabe, Jun-ichi Narita, Hideaki Hagiwara, Mark Noble, K. Nomura, H. Oyama, M. Motoo, S. Shibui, K. Tokuue, Y. Akine, Svein J. Tjoflaat Nygaard, F. S. Pardo, D. W. Hsu, E. T. Hedley-Whyte, J. Efird, E. V. Schmidt, Paal-Henning Pedersenl Kirsten Marienhagen, Geoffrey J. Pilkington, Tracey M. Clarke, Hui Tian Yu, Joan P. Rogers, Robert Stern, Surasak Phuphanich, Harvey Greenberg, R. Murtagh, Jesus Viloria, Joseph Ransohoff, Kimberly Martin, V. Erika Hatva, Jasti S. Rao, S. Mohanam, Sandra A. Rempel, Karl Schwechheimer, Richard L. Davis, Webster K. Cavenee, Mark L. Rosenblum, Guido Reifenberger, Lu Liu, Koichi Ichimura, Esther E. Schmidt, V. Peter Collins, T. Revesz, F. Scaravilli, H. Cockburn, R. T. Biron, James McKerrow, Bonnie Sloane, Tom Mikkelsen, Norbert Roosen, Peter Coopersmith, Robert Smith, Harcharan Kaur Rooprai, Steven Maidment, Garry Rucklidge, Anton Volovsek, J. T. Rutka, S. L. Smith, K. Matsuzawa, A. A. Sankar, S. R. Williams, K. Fukuyama, Jun Ikeda, R. G. Selker, F. T. Vertosick, M. T. Goldenberg, R. Bindal, A. Taratuto, P. Picco, J. Monges, M. Martinez, G. Pacheco, M. Gamboni, M. Schultz, B. A. Mueller, T. G. Ewers, T. Shiraishi, K. Tabuchi, S. Nakagawa, S. Kihara, D. J. Stewart, L. Eapen, O. Agboola, P. Popovic, R. Goel, P. Raaphorst, P. T. T. Wong, S. Shimokawa, M. Oh-uchida, K. Hori, C. Markert, K. -W. Pflughaupt, A. -C. Diserens, R. Jauferrally, M. -F. Hamou, H. Takeshima, H. Mochizuki, J. L. Clifford, T. Nishi, R. Lotan, A. J. A. Terzis, H. Arnold, O. D. Laerum, R. Bjerkvig, A. L. Taratuto, G. Sevlever, D. Diaz, M. Di Tella, V. Cuccia, H. Pomata, G. Gallo, A. Dietze, U. Knopp, R. Thomas, P. Carnochan, G. Flux, N. Kitchen, D. Thomas, M. Zalutsky, D. Bigner, Philip Tofilon, Paul Borchardt, Sverre H. Torp, Are Dalen, Takashi Tohyama, Osami Kubo, Kintomo Takakura, Virginia M. -Y. Lee, John Q. Trojanowski, Svein Nygaard, M. B. Parliament, A. J. McEwan, R. H. Mannan, L. I. Weibe, G. Unsgårp, U. Sonnewald, I. Gribbestad, E. Isern, S. B. Petersen, J. Wang, D. A. Delgado, Tracy J. Warr, Denise Sheer, Pat Gorman, F. Yamaguchi, M. Westphal, L. Anker, W. Hamel, M. Lücke, M. Shepard, P. Kleihues, H. D. Herrmann, W. K. Alfred Yung, Scott Taylor, and Peter A. Steck

Subjects
Cancer Research, medicine.medical_specialty, Neurology, Oncology, business.industry, Medicine, Medical physics, Neurology (clinical), business
Published
1993

12. Intraoperative imaging techniques in the treatment of brain tumors

Author

G E Keles, M S Berger, and R Zakhary

Subjects
Cancer Research, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Brain Neoplasms, Magnetic resonance imaging, Brain tissue, Magnetic Resonance Imaging, Lesion, Stereotaxic Techniques, Intraoperative Period, Oncology, Stereotaxic technique, Medical imaging, Medicine, Humans, Displacement (orthopedic surgery), Radiology, medicine.symptom, business, Tomography, X-Ray Computed, Intraoperative imaging, Ultrasonography
Abstract

Despite significant advances in medical imaging techniques and their routine preoperative use, real-time intraoperative information regarding anatomy remains of indisputable importance to neurosurgeons. Intraoperative displacement of the brain tissue caused by surgical retraction or the resection cavity itself, as well as shift caused by cerebrospinal fluid leakage, may result in alteration of the surgical anatomy of the lesion and surrounding structures. Neurosurgical navigation methods are beneficial in providing accurate intraoperative information regarding the anatomy of the surgical field. Furthermore, interactive image guidance may decrease incision lengths, operating times, and postoperative morbidity. This review focuses on recent developments in neurosurgical navigational techniques that enable real-time anatomic visualization during brain tumor surgery.

Published
1999

13. Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC)

Author

Helen J. Ross, M. S. Berger, M. T. Schreeder, Ravi Salgia, L. J. Blakely, Q. S. Chu, Alberto Chiappori, Deepa S. Subramaniam, M. M. Moezi, and J. Stephenson

Subjects
Oncology, Cancer Research, Schedule, medicine.medical_specialty, business.industry, Antagonist, Cns effects, Carboplatin, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, business, Adverse effect, Extensive-stage small cell lung cancer, Etoposide, Obatoclax, medicine.drug
Abstract

e13531 Background: Previous studies with obatoclax (Ob), a pan-BCL-2 antagonist, identified infusional CNS effects as dose- limiting adverse events (AEs) that occur with greater frequency and inten...

Published
2010

14. A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)

Author

M. T. Schreeder, Q. S. Chu, M. M. Moezi, M. M. Modiano, Shakun Malik, J. L. Blakely, Alberto Chiappori, Ravi Salgia, J. Stephenson, and M. S. Berger

Subjects
Cisplatin, Cancer Research, business.industry, Antagonist, In vitro, Carboplatin, Bcl-2 Inhibitor, chemistry.chemical_compound, Oncology, chemistry, Cancer research, Medicine, business, Extensive-stage small cell lung cancer, Etoposide, medicine.drug, Obatoclax
Abstract

3576 Background: Obatoclax (Ob) is a small-molecule antagonist of all the Bcl-2 prosurvival proteins. In vitro it enhances the effects of the drugs cisplatin and etoposide. Bcl-2 family proteins are frequently expressed in SCLC, and SCLC cell lines are sensitive to Ob. Methods: This study was designed to find the maximal tolerated doses (MTD) of oOb when given on a 21 day (D) cycle together with carboplatin (AUC 5 D1) and etoposide (100 mg/m2 D1–3), in separate dose escalations using Ob as a 3-hr infusion D1–3 and as a 24-hr infusion D1–3. Eligible patients had ES-SCLC, measurable disease, ≤1 prior therapy, ECOG PS ≤1, and adequate hematological, renal and hepatic function. 3- 6 patients were enrolled into ascending dose cohorts with standard DLT rules evaluating safety in C1 to determine dose escalation. Results: 24 patients were enrolled into 5 dosing cohorts (14 males; median age 67). A total of 66 cycles (C) have been administered to date. There were no DLTs in the initial cohorts using Ob 15 mg over 3 hr or Ob 30 mg over 24 hr. Two DLTs occurred in the Ob 30 mg over 3 hr cohort - both due to myelosuppression in previously treated patients. As a result, the trial was amended to exclude previously treated patients. 5 previously untreated patients receiving Ob 30 over 3 hr had no DLTs. There were no DLTs in the Ob 45 mg over 24 hr cohort but 2 patients in the Ob 24-hr infusion cohorts had infusion pump malfunctions while at home. There were 2 DLTs in the Ob 45 mg over 3 hr cohort (somnolence, euphoria, & disorientation) establishing MTD of Ob 30 mg over 3 hr daily x 3. After C2 the 6 previously untreated patients on Ob 24-hr infusion cohorts had 3 PRs, 1 SD, 1 PD, and 1 Unk; the 2 previously treated patients had PRs. After C2 all 7 previously-untreated patients at 15 or 30 mg in the 3-hr infusion cohorts have PR; the 3 previously treated patients had SD. Conclusions: Ob can be combined with carboplatin and etoposide using either a 3-hr or a 24-hr infusion, and both regimens are associated with high early response rates in ES-SCLC, perhaps due to inhibition of mcl-1. Due to practical issues with the 24-hr infusion arm, the 3-hr 30 mg MTD dose will be utilized in a randomized phase II versus carboplatin and etoposide alone. [Table: see text]

Published
2009

15. 592 POSTER Obatoclax (GX17–070), a small molecule pan-bcl-2 inhibitor, in combination with docetaxel in a phase I/II trial enrolling patients with relapsed non-small cell lung cancer (NSCLC)

Author

Martin J. Edelman, Donald W. Northfelt, Charles Williams, J. Adams, D. A. Van Echo, Peter Rosen, M. S. Berger, Eric B. Haura, Shakun Malik, and Alberto Chiappori

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, Small molecule, Bcl-2 Inhibitor, chemistry.chemical_compound, Phase i ii, Docetaxel, chemistry, Internal medicine, Medicine, business, medicine.drug, Obatoclax
Published
2008

16. A phase I trial of the small molecule pan-bcl-2 inhibitor obatoclax (GX15–070) in combination with docetaxel in patients with relapsed non-small cell lung cancer (NSCLC)

Author

D. A. Van Echo, M. S. Berger, Donald W. Northfelt, Martin J. Edelman, Eric B. Haura, J. Adams, Shakun Malik, Alberto Chiappori, and Charles Williams

Subjects
Cisplatin, Oncology, Cancer Research, medicine.medical_specialty, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, Small molecule, respiratory tract diseases, Bcl-2 Inhibitor, chemistry.chemical_compound, chemistry, Docetaxel, Apoptosis, Internal medicine, medicine, In patient, business, neoplasms, medicine.drug, Obatoclax
Abstract

19035 Background: Over expression of bcl-2 family proteins is common in NSCLC and the BH-3 mimetic obatoclax (O) induces apoptosis in a subset of NSCLC where it synergizes with cisplatin (Li et al....

Published
2008

17. Omental transposition to bypass the blood brain barrier for delivery of chemotherapeutic agents to malignant brain tumours: preclinical investigation

Author

E. Z. Longa, M. S. Berger, Philip Weinstein, R. Hattner, B. Perira, and H. S. Goldsmith

Subjects
medicine.medical_specialty, education.field_of_study, business.industry, Incidence (epidemiology), Mortality rate, Central nervous system, Population, Disease, medicine.disease, Blood–brain barrier, Cerebrospinal fluid, medicine.anatomical_structure, medicine, Radiology, Moyamoya disease, education, business, Neuroscience
Abstract

Primary neoplasms of the central nervous system (CNS) occur with an approximate incidence of 4.5 cases per 100 000 population annually, and approximately 25% to 35% of these tumours are malignant (1,2). Despite aggressive new approaches in treating these lesions, the mortality rate has not changed dramatically over the past ten to 15 years. This is extremely disappointing when one considers that patients succumb to this disease due primarily to the effects of local recurrence and subsequent mass effect (1). Malignant gliomas rarely metastasize outside the CNS (3), and, indeed, infrequently result in death due to cerebrospinal fluid dissemination and/or multicentricity. Hochberg (4) demonstrated that 90% to 95% of recurrences of malignant gliomas occur within two centimetres of the contrast enhancing margin as depicted by computed tomography (CT) scans.

Published
1990

18. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history

Author

Frances A. Shepherd, Afshin Dowlati, Helen J. Ross, H. Hassani, James R. Rigas, Tal Zaks, M. S. Berger, Jennifer Garst, Michael Smylie, and George R. Blumenschein

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.drug_class, business.industry, non-small cell lung cancer (NSCLC), Lapatinib, medicine.disease, Tyrosine-kinase inhibitor, Smoking history, Surgery, Second line, Internal medicine, Multicenter trial, medicine, Carcinoma, Clinical endpoint, business, medicine.drug
Abstract

7611 Background: LAP (GW572016) is an oral reversible, dual tyrosine kinase inhibitor of EGFR (ERBB1) and HER2/neu (ERBB2). This study was designed to test the activity of 2 dose schedules of LAP in chemotherapy naïve pts with NSCLC; it was amended to target patients with either BAC or no smoking history in the first or second line and to evaluate the relationship of mutations in target genes to responses. Methods: LAP was given orally 1,500 mg once (QD) or 500 mg twice daily (BID) until progression or intolerance. Safety and efficacy (RECIST) were assessed every 4 & 8 weeks. The primary endpoint was response. The target (BAC/no smoking) and non- target populations were assessed for efficacy, and tumor tissue was analyzed for ERBB1 and ERBB2 mutations and/or amplifications. Results: The study was stopped for futility after 131 pts were randomized (65 QD, 66 BID). Median age 66 (range 32–86); female 56%; BAC 20%, No BAC 71%; previously untreated 98.5%; current/former smokers 70%, never smoker 30%. There were no complete responses. Of 56 pts in the target population, 1 (2%) achieved partial response (PR), 11 (20%) had stable disease (SD) of ≥24 wks; in the non-target population, 1 pt had a PR (1.3%) and 12 (16%) had SD of ≥24 wks. 3 pts had ERBB1 mutations (G719S, S768I, KRAS G12S; L858R and T790M; L858R) but none of them responded. There were no ERBB2 mutations. Three of 77 pts evaluated had ERBB1 gene copy increase (none of whom responded) and 2 had ERBB2 gene copy increase (one had a 51% decrease in tumor size). The most common adverse events were grade 1/2 diarrhea, nausea, rash, vomiting and fatigue, and were similar in both groups. Conclusions: LAP was well-tolerated, with no notable difference in toxicity between the QD and BID groups. Very few responses were seen, stable disease was sometimes prolonged. The prevalence of mutations was low even in the target population. Given the preclinical synergy between LAP and other agents, further studies will be necessary to determine whether LAP is active in combination with other agents for the treatment of NSCLC. [Table: see text]

Published
2007

19. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Author

Christopher M. Nutting, J. H. Bourhis, M. S. Berger, Dominique Rosine, A. P. Beelen, S. Gardiner, A. G. Stead, Kevin J. Harrington, A. M. Theodosiou, and I. A. El-Hariry

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Locally advanced, Lapatinib, Open label study, Internal medicine, medicine, Basal cell, In patient, Head and neck, business, Competitive inhibitor, medicine.drug
Abstract

5553 Background: Lapatinib is a selective and potent dual, competitive inhibitor of EGFR and ErbB2. A high level of expression of EGFR is reported in SCCHN (ranging from 55% to 90%), which is a negative prognostic factor, whereas ErbB2 expression ranges between 40% to 60%. The rationale for EGFR inhibition in combination with fractionated radiotherapy is to enhance radiosensitivity and inhibit cellular proliferation, including accelerated repopulation, during treatment. Methods: Patients (pts) with locally advanced SCCHN were enrolled at escalating dose levels of lapatinib (500–1,500 mg/d) in combination with radiotherapy (66–70 Gy/6–7 weeks given 5 days a week in 2 Gy daily fractions) and intravenous cisplatin (100 mg/m2, days 1, 22 and 43 of radiotherapy). Each cohort was to include 3 pts, with expansion to 6 in the event of dose-limiting toxicity (DLT). Main eligibility criteria were confirmed SCCHN, excluding nasopharynx, stage III, IVa,b, and adequate organ function. Regular safety assessments were performed during therapy and follow-up period. Cardiac assessments using MUGA or ECHO scans were also performed. Results: Seventeen pts were treated (500 mg - 7; 1,000 mg - 7; 1,500 mg - 3; expanded cohort of 9 additional pts is currently recruiting). The most common side effects were Grade 1-3 dysphagia, mucositis and dermatitis, typically observed with cisplatin and radiotherapy in this population. Lapatinib-related adverse events were minor. In the 500mg cohort: 2 pts had diarrhea (Gr 1), 1 pt had tinnitus (Gr 1); in the 1,000mg cohort: 2 pts had nausea (Gr 2) and vomiting (Gr 2), 1 pt had transient elevated liver enzymes (Gr 3); in the 1,500mg cohort 2 pts had nausea (Gr 1) and 3 pts vomiting (1 pt Gr 1, and 2 pts Gr 2). One DLT was reported both at 500 mg and 1,000 mg dose levels; no further DLT were reported at the final 1,500 mg dose level. The optimally tolerated regimen was lapatinib 1,500 mg OD, given concurrently with conventional radiotherapy and cisplatin. Preliminary evidence of clinical activity was encouraging. Conclusions: The combination of lapatinib and concomitant chemoradiation is well tolerated, has demonstrated encouraging clinical activity in this population of locally advanced SCCHN patients, and warrants phase II studies in this disease. [Table: see text]

Published
2006

20. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Author

K. J. Brill, D. A. Rinaldi, M. S. Berger, C. A. Henderson, C. J. Germond, L. H. Leopold, A. L. A. Fields, and L. Chu

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Colorectal cancer, Phases of clinical research, medicine.disease, Lapatinib, Oxaliplatin, Irinotecan, ErbB, Internal medicine, Toxicity, medicine, skin and connective tissue diseases, business, Adverse effect, medicine.drug
Abstract

3583 Background: Lapatinib is an orally active, reversible inhibitor of the tyrosine kinase activity of ErbB1 (EGFR) and ErbB2 (HER-2/neu). This multicenter, open-label, phase II study was designed to evaluate the safety and efficacy of single-agent lapatinib in patients with metastatic colorectal carcinoma, whose tumors progressed on first-line therapy with 5-fluorouracil in combination with irinotecan or oxaliplatin. Methods: Eighty-six (86) patients received 1250mg of oral lapatinib daily until disease progression or unacceptable toxicity. Safety and efficacy assessments were performed at 4-week and 8-week intervals respectively. Tumor response was determined by an independent review committee using RECIST guidelines. Results: The median age was 60 years (22–83) and median KPS was 90 (70–100). Patients were not selected based on ErbB expression; however, 54.2% and 44.1% of the patients had positive expression (+1, +2, +3) for ErbB1 and ErbB2, respectively. The most commonly encountered adverse events w...

Published
2005

21. Pap Smear Adequacy

Author

B R Kane, Lisney M, and M S Berger

Subjects
Cervical cancer, medicine.medical_specialty, Pap smears, Scoring system, business.industry, Obstetrics and Gynecology, Papanicolaou stain, General Medicine, medicine.disease, Cervical smears, Medical risk, Family medicine, Retrospective analysis, Medicine, lipids (amino acids, peptides, and proteins), Smear sample, business
Abstract

BACKGROUND AND OBJECTIVES The Papanicolaou (Pap) smear is a widely accepted tool for the detection and prevention of cervical cancer. Under the Bethesda Scoring System, the key internal control for adequacy of the smear is the presence of endocervical cells. Over the past several decades, much effort has been undertaken to maximize the adequacy of this acquisition. The present study determined if Pap smear sample adequacy is related to clinician experience. METHODS This study includes a retrospective analysis of 1,356 Pap smears acquired between January 1992 and January 1995. The procedures were performed by family practice residents and faculty physicians. Cervical smears were obtained with a combination of a cytobrush and an Ayre spatula and were placed on two slides. Adequacy was subsequently determined by a cytotechnologist. Chi-square analysis was used to determine if the adequacy rates for faculty and for PGY-1, PGY-2, and PGY-3 residents were significantly different. RESULTS The adequacy rates for PGY-1, PGY-2, PGY-3 residents and faculty physicians were 80%, 89%, 89%, and 93%, respectively. The adequacy rates for the first-year residents were significantly different from that of all other studied groups. CONCLUSIONS This study demonstrates the relationship between clinician experience and the ability to perform an adequate Pap smear. Considering the cost and potential medical risk of an inadequate Pap smear, family practice residency programs should increase the degree of PGY-1 education and experience in performing Pap smears.

Published
1998

22. Confidentiality and Health Insurance Fraud

Author

Joan Weiner, Peter A. Ubel, N J Farber, Boyer Eg, M S Berger, and Elizabeth B. Davis

Subjects
Insurance fraud, medicine.medical_specialty, business.industry, MEDLINE, Group insurance, humanities, Underinsured, Vignette, Family medicine, Ethical dilemma, Health care, Internal Medicine, Medicine, Confidentiality, business, health care economics and organizations
Abstract

Background: Health insurance fraud committed by patients may be an increasing problem given the number of underinsured and uninsured people in the United States. Physicians recognizing acts of health insurance fraud perpetrated by patients face an ethical dilemma: should they disclose the incident to the insurance company, or protect patient confidentiality? Objective: To explore physicians' attitudes toward the reporting of patient-initiated health insurance fraud. Methods: Three hundred seven physician members of the American College of Physicians returned a mailed questionnaire that presented 6 case vignettes (3 variables) of patients who used a relative's insurance to obtain health care in the past. For each vignette, respondents were asked whether the treating physician should report insurance fraud to the health insurance carrier. Results: Sixty-three respondents (20.7%) indicated that physicians should report all the patients presented in the vignettes, while 45 (14.8%) indicated none should be reported; the rest indicated that the decisions to report should be based on the characteristics presented, with acute vs terminal illness ( P P P P =.04) and respondents' experiences with insurance fraud (P=.03) had significant effects on the willingness to report patients. Conclusions: Physicians are divided about whether to report patients who have committed insurance fraud. Their decisions to report insurance fraud are influenced by their attitudes and demographic features, as well as by patient factors. Arch Intern Med. 1997;157:501-504

Published
1997

23. Radiation-induced meningiomas in pediatric patients

Author

Gaylan L. Rockswold, S. D. Moss, M. S. Berger, Douglas H. Yock, and Shelley N. Chou

Subjects
Male, medicine.medical_specialty, Neoplasms, Radiation-Induced, medicine.medical_treatment, Radiation induced, Meningioma, otorhinolaryngologic diseases, medicine, Humans, Cerebellar Neoplasms, neoplasms, Medulloblastoma, medicine.diagnostic_test, Brain Neoplasms, Retinoblastoma, business.industry, Eye Neoplasms, Infant, Magnetic resonance imaging, medicine.disease, Magnetic Resonance Imaging, Leukemia, Lymphoid, nervous system diseases, Surgery, Radiation therapy, Leukemia, Pediatric patient, Child, Preschool, Female, Neurology (clinical), Tomography, X-Ray Computed, business
Abstract

Radiation-induced meningiomas rarely have latency periods short enough from the time of irradiation to the clinical presentation of the tumor to present in the pediatric patient. Three cases of radiation-induced intracranial meningiomas in pediatric patients are presented. The first involved a meningioma of the right frontal region in a 10-year-old boy 6 years after the resection and irradiation of a 4th ventricular medulloblastoma. Review of our pediatric tumor cases produced a second case of a left temporal fossa meningioma presenting in a 15-year-old boy with a history of irradiation for retinoblastoma at age 3 years and a third case of a right frontoparietal meningioma in a 15-year-old girl after irradiation for acute lymphoblastic leukemia. Only three cases of meningiomas presenting in the pediatric age group after radiation therapy to the head were detected in our review of the literature.

Published
1988

24. THE ANESTHETIC EFFECTS OF ETHYL VINYL ETHER, DIVINYL ETHER, AND DIETHYL ETHER ON MICE

Author

J. B. Aycrigg, M. S. Berger, and E. Trier Morch

Subjects
business.industry, organic chemicals, Induction time, Ether, Medicinal chemistry, chemistry.chemical_compound, chemistry, Ethyl vinyl, Ethyl vinyl ether, Anesthetic, Medicine, Surgical anesthesia, Diethyl ether, business, medicine.drug
Abstract

1. Experiments were carried out to determine the anesthetic effects of divinyl, ethyl vinyl and diethyl ether on mice. 2. The concentrations necessary to produce surgical anesthesia and respiratory arrest were, for divinyl ether 8 and 12 vol. per cent, for ethyl vinyl ether 6 and 16 vol. per cent and for diethyl ether 6 and 18 vol. per cent. Induction time was short and nearly the same for the three ethers in the range 8-14 vol. per cent. Recovery was prolonged following anesthesia with diethyl ether especially when higher concentrations were used. Thus, our results indicate that divinyl ether is the least potent agent for producing surgical anesthesia and the most potent for producing respiratory arrest. It is, therefore, the most dangerous of the three ethers. Ethyl vinyl ether was found to be rapid in action, potent and safe. Recovery time following its use was short.

Published
1957

Catalog

Books, media, physical & digital resources
See catalog results